TREATMENT OPTIMIZATION IN ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG

PFIZER, S.A

Object

Topic: Oncology.

Destination: Projects in scope include creation and deployment of educational content or programs. Projects that will be considered for Pfizer support will focus on the following educational topics:

  • Latest clinical data updates relevant to the treatment of patients with advanced or metastatic ALK-positive NSCLC.
  • Elements of optimal clinical management of these patients, e.g., mitigation of adverse events, and dose modification.
  • Role of the caregiver in clinical management, e.g., dose modification/compliance, adverse event identification.

Budget: Up to $250,000/project

Duration: Not indicated.

Are you interested int his call?

Are you interested?

Fill out the form below to receive more information: